Patents by Inventor James A. Shayman

James A. Shayman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same
    Publication number: 20230212123
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Application
    Filed: April 20, 2021
    Publication date: July 6, 2023
    Inventors: Scott D. Larsen, James A. Shayman, Michael William Wilson, Neil Moss
  • Glucosylceramide synthase inhibitors and therapeutic methods using the same
    Patent number: 11220479
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: January 11, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Scott D. Larsen, James A. Shayman, Kim Hutchings, Neil Moss, Qin Jiang, Nicholas Mayhew, Emily Freeman, Zohreh Sajjadi Hashemi
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
    Publication number: 20210122712
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Application
    Filed: October 22, 2020
    Publication date: April 29, 2021
    Inventors: Scott D. Larsen, James A. Shayman, Kim Hutchings, Neil Moss, Qin Jiang, Nicholas Mayhew, Emily Freeman, Zohreh Saijadi Hashemi
  • Glucosylceramide synthase inhibitors and therapeutic methods using the same
    Patent number: 10202340
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: February 12, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Scott D. Larsen, Akira Abe, Liming Shu, Michael William Wilson, Richard F. Keep, Duxin Sun, James A. Shayman
  • Method of reducing accumulation of intracellular tingible body macrophages
    Patent number: 10111937
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: October 30, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
    Publication number: 20180022697
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 25, 2018
    Inventors: Scott D. Larsen, Akira Abe, Liming Shu, Michael William Wilson, Richard F. Keep, Duxin Sun, James A. Shayman
  • Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and Treating Systemic Lupus Erythematosus
    Publication number: 20160317626
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Application
    Filed: April 11, 2016
    Publication date: November 3, 2016
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus
    Patent number: 9309553
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: April 12, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Glucosylceramide synthase inhibitors and therapeutic methods using the same
    Patent number: 8961959
    Abstract: Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: February 24, 2015
    Assignee: The Regents of the University of Michigan
    Inventors: Scott Larsen, Akira Abe, Liming Shu, Michael William Wilson, Richard F. Keep, James A. Shayman
  • Lysosomal Phospholipase A2 (LPLA2) Activity as a Diagnostic and Therapeutic Target for Identifying and treating Systemic Lupus Erythematosis
    Publication number: 20120121571
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Application
    Filed: October 13, 2011
    Publication date: May 17, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
    Patent number: 8052970
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: November 8, 2011
    Assignee: The Regents of the University of Michigan
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • LYSOSOMAL PHOSPHOLIPASE A2 (LPLA2) ACTIVITY AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR IDENTIFYING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSIS
    Publication number: 20090324575
    Abstract: The present invention is directed to methods for diagnosis and treatment of systemic lupus erythematosus and drug-induced systemic lupus erythematosus. More specifically, the specification describes methods using a lysosomal phospholipase A2 in methods for the diagnosis and treatment of autoimmune disorders such as systemic lupus erythematosus and drug-induced systemic lupus erythematosus.
    Type: Application
    Filed: June 30, 2009
    Publication date: December 31, 2009
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James A. Shayman, Akira Abe, Robert Kelly, Jessica Kollmeyer, Ye Lu
  • Amino ceramide-like compounds and therapeutic methods of use
    Publication number: 20090312392
    Abstract: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
    Type: Application
    Filed: April 30, 2009
    Publication date: December 17, 2009
    Inventors: James A. Shayman, David J. Harris, Craig Siegel, Carol A. Nelson, Diane P. Copeland
  • Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
    Patent number: 7615573
    Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: November 10, 2009
    Assignees: The Regents of the University of Michigan, Genzyme Corporation
    Inventors: Craig Siegel, James A. Shayman, Carol A. Nelson, David J. Harris, Diane P. Copeland
  • Methods and compositions for using aleveolar macrophage phospholipase A2
    Patent number: 7582442
    Abstract: The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: September 1, 2009
    Assignee: The Regents of the University of Michigan
    Inventors: James A. Shayman, Akira Abe, Miki Hiraoka
  • Amino ceramide-like compounds and therapeutic methods of use
    Publication number: 20080146533
    Abstract: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
    Type: Application
    Filed: July 27, 2007
    Publication date: June 19, 2008
    Inventors: James A. Shayman, David J. Harris, Craig Siegel, Carol A. Nelson, Diane P. Copeland
  • Amino ceramide-like compounds and therapeutic methods of use
    Patent number: 7335681
    Abstract: Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: February 26, 2008
    Assignee: The Regents of the University of Michigan
    Inventor: James A. Shayman
  • Methods and compositions for using alveolar macrophage phospholipase A2
    Patent number: 7319015
    Abstract: The present invention is directed to methods and compositions for improving pulmonary surfactant catabolism. More specifically, the specification describes methods and compositions for making and using a lysosomal phospholipase A2 in methods for the diagnosis, and treatment of disorders of phospholipid catabolism such as pulmonary alveolar proteinosis.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: January 15, 2008
    Assignee: The Regents of The University of Michigan
    Inventors: James A. Shayman, Akira Abe, Miki Hiraoka
  • Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
    Publication number: 20070203223
    Abstract: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
    Type: Application
    Filed: February 5, 2007
    Publication date: August 30, 2007
    Inventors: Craig Siegel, James Shayman, Carol Nelson, David Harris, Diane Copeland
  • Amino ceramide-like compounds and therapeutic methods of use
    Patent number: 7253185
    Abstract: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: August 7, 2007
    Assignees: The Regents of the University of Michigan, Genzyme Corporation
    Inventors: James A. Shayman, David J. Harris, Craig Siegel, Carol A. Nelson, Diane P. Copeland